SCHEMBL4191882

SCHEMBL4191882

CCCOc1ccc(C(=O)Nc2ccc(C(=O)N(C)O)cc2)cc1OCCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
KDM4E B2RXH2 3/20 0.53
HSD17B10 Q99714 2/20 0.53
TSHR P16473 2/20 0.53
ALDH1A1 P00352 1/20 0.53
RAB9A P51151 1/20 0.53
MCL1 Q07820 1/20 0.53
PDE4D Q08499 1/20 0.51
LMNA P02545 1/20 0.51
MAPK14 Q16539 1/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HPSE Q9Y251 1/20 0.46
GAA P10253 1/20 0.45
POLB P06746 1/20 0.45
MCHR1 Q99705 1/20 0.45
CREBBP Q92793 1/20 0.45
SMPD1 P17405 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4186685 0.90 MAPK14 (0.56) MAPTKDM4ETSHRALDH1A1RAB9A
SCHEMBL16613183 0.81 PDE4D (0.54) MAPTKDM4EHSD17B10TSHRALDH1A1
SCHEMBL4183893 0.81 KMT2A (0.65) MAPTALDH1A1RAB9ALMNAMEN1
SCHEMBL4024140 0.79 HDAC1 (0.57) MAPTKDM4EHSD17B10ALDH1A1RAB9A
SCHEMBL4191625 0.79 ALDH1A1 (0.57) MAPTKDM4EHSD17B10TSHRALDH1A1
SCHEMBL4180097 0.78 MEN1 (0.45) MAPTKDM4EALDH1A1RAB9AMCL1
SCHEMBL8387145 0.77 CNR2 (0.66) MAPTLMNAHDAC1HDAC2SMPD1
SCHEMBL8420347 0.73 MAPT (0.59) MAPTKDM4EHSD17B10ALDH1A1RAB9A
SCHEMBL4020644 0.73 HDAC1 (0.58) MAPTKDM4EPDE4DLMNAHDAC1
SCHEMBL9877204 0.71 CACNA1B (0.65) MAPTKDM4EALDH1A1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485750-B2 Hydroxamic acid derivatives and the preparation method thereof AMOREPACIFIC CORPORATION (KR) 2009-02-03 US disclosed
US-20080242730-A1 Hydroxamic Acid Derivatives and the Preparation Method Thereof AMOREPACIFIC CORPORATION (KR) 2008-10-02 US disclosed
EP-1874722-A1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF Amorepacific Corporation (KR) 2008-01-09 EP disclosed
WO-2006118380-A1 HYDROXAMIC ACID DERIVATIVES AND THE PREPARATION METHOD THEREOF AMOREPACIFIC CORPORATION (KR) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242730-A1 Hydroxamic Acid Derivatives and the Preparation Method Thereof COL14A1, CUTA, COL2A1 MAPT 4518/4885KDM4E 340/4885HSD17B10 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.